Highest-materiality recent filing
60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.
Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M
FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.
Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer
ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.
Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D
Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.
Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026
Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).
Relay's zovegalisib granted FDA Breakthrough Therapy Designation for PIK3CA-mutant breast cancer
FDA granted Breakthrough Therapy Designation to zovegalisib + fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6i.
Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors
Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.
Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial
Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.
Relay Therapeutics terminates Binney St lease early, signs Kendall Square lease; saves ~$16M in rent
Paid $2.5M modification fee and transferred FF&E to landlord to terminate Binney St lease early.
On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.
Max materiality 0.75 · Median 0.65 · Most common event other_material